Topical testosterone products quantity management (coverage criteria)
Defines quantity limits and medical necessity criteria for topical testosterone formulations (patches, gels, nasal, solution, buccal) for Cigna-administered health benefit plans; affects prescribers and pharmacists requesting coverage or overrides.
Brand AndroGel 1% gel pump was removed from the policy (not available); the generic is still available and included in the policy.
The generic Vogelxo metered dose pump was added to the policy (previously only the brand was available).
Override criteria language for Androderm 4 mg, AndroGel 1.62% gel pump (generic), and Fortesta (generic) for Female-to-Male Gender Reassignment was updated to 'Gender-Dysphoric/Gender-Incongruent Persons/Female-to-Male (FTM) Gender Reassignment.'
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.